Vanguard Personalized Indexing Management LLC Buys 1,518 Shares of Natera, Inc. (NASDAQ:NTRA)

Vanguard Personalized Indexing Management LLC grew its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 16.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,009 shares of the medical research company’s stock after acquiring an additional 1,518 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Natera were worth $1,189,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of NTRA. GAMMA Investing LLC raised its stake in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares in the last quarter. YHB Investment Advisors Inc. purchased a new stake in shares of Natera during the 1st quarter worth $36,000. Principal Securities Inc. purchased a new stake in shares of Natera during the 4th quarter worth $32,000. Tobam bought a new stake in Natera during the second quarter valued at about $74,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in Natera in the first quarter valued at about $83,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

NTRA has been the topic of a number of recent analyst reports. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a report on Wednesday, August 28th. Morgan Stanley raised their target price on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. BTIG Research upped their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. UBS Group lowered their price objective on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Finally, TD Cowen upped their target price on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average target price of $120.07.

Insider Transactions at Natera

In other Natera news, insider Jonathan Sheena sold 2,700 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $108.87, for a total value of $293,949.00. Following the completion of the transaction, the insider now directly owns 301,808 shares of the company’s stock, valued at $32,857,836.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $108.87, for a total transaction of $293,949.00. Following the completion of the transaction, the insider now directly owns 301,808 shares of the company’s stock, valued at approximately $32,857,836.96. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 5,024 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the sale, the chief executive officer now directly owns 195,686 shares in the company, valued at $25,141,737.28. The disclosure for this sale can be found here. Insiders have sold 93,921 shares of company stock worth $10,551,281 over the last quarter. 7.60% of the stock is currently owned by insiders.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $127.78 on Monday. The company has a 50 day simple moving average of $114.45 and a two-hundred day simple moving average of $105.54. The stock has a market cap of $15.69 billion, a price-to-earnings ratio of -40.96 and a beta of 1.53. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $132.01.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same period in the previous year, the firm posted ($0.97) earnings per share. The firm’s quarterly revenue was up 58.1% on a year-over-year basis. As a group, analysts predict that Natera, Inc. will post -1.96 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.